Takeda’s Eohilia Sees Strong Early Adoption and Growth Potential in Eosinophilic Esophagitis, According to Spherix Global Insights
2024年7月18日 - 11:05PM
In February of this year, Takeda’s Eohilia (budesonide oral
suspension) received FDA approval as the first and only oral
therapy for eosinophilic esophagitis (EoE) in patients aged 11 and
older. This follows the approval of Sanofi/Regeneron’s Dupixent
(dupilumab) in 2022. Recent analysis from Spherix Global Insights’
Launch Dynamix™: Eohilia in EoE study indicates that,
despite being on the market for only a few months, Eohilia has
already made significant strides in adoption and is poised for
rapid growth.
At approximately three months post-launch, EoE treaters in the
analysis (n=63 US gastroenterologists and n=12 US allergists)
report trial rates comparable to Dupixent at a similar post-launch
timeframe, with over half already experienced in prescribing
Eohilia. Additionally, the breadth of patient initiations for
Eohilia surpasses that of its biologic competitor at the
three-month milestone.
Takeda’s brand is also poised for significant growth and market
penetration. Six-month projections indicate a user base comparable
to Dupixent's, with EoE patient share for Eohilia expected to
increase fourfold.
As a recently approved product in a condition with a substantial
unmet need, Eohilia’s expected efficacy and an improved approach to
the administration of a trusted compound are key factors driving
uptake. As one physician shared, “I have probably started six or
seven patients on Eohilia. I am excited to have this drug. I have
been treating this disease for 15 to 20 years and using topical
steroids for most of that time. This is an improvement over what we
had, and I am going to use more of it going forward.”
The direct impacts on Dupixent from increased adoption of
Eohilia are yet to materialize, though a majority of respondents
indicate that they expect Eohilia to delay their use of Dupixent in
EoE patients. Furthermore, two-fifths of the most recent
Eohilia prescriptions would have been for Dupixent had Takeda’s
brand not been available.
One key concern among EoE market observers is the potential
impact of Eohilia's 12-week treatment label. Although it is still
early in the launch phase to assess how consecutive treatment
courses will be managed, a significant number of prescribers have
indicated a preference for continuing treatment immediately after
the initial 12-week period. Looking ahead at their plans, one
treating physician offers, “It's enough time for induction, but
it's not enough time for long-term maintenance, because if you just
treat a patient for 12 weeks and you stop the treatment, the
disease will come back…So this is a scenario that I'm going to
encounter very shortly because the six patients or so are all up
for their repeat endoscopies. I'm probably going to do one of two
things: After I repeat a scope, and if they are indeed in
remission, I'm going to probably reduce [Eohilia] to once a day
off-label. If the insurance does not cover, I'll switch them to
sort of generic budesonide.”
Spherix will continue to monitor Eohilia’s uptake, including the
persistence of consecutive prescriptions, and launch performance
comparisons via the Launch Dynamix™ service.
Additionally, Spherix will explore gastroenterologist and allergist
perspectives on the overall EoE market and pipeline products in its
upcoming Market Dynamix™ service.
Launch Dynamix™ is an independent service providing
monthly benchmarking of newly launched products for the first
eighteen months of commercial availability, augmented by a
quarterly deep dive into promotional activity, barriers to uptake,
and patient types gravitating to the launch brand.
Market Dynamix™ is an independent service
providing analysis of markets anticipated to experience a paradigm
shift within the next three to five years. Insights highlight
market size, current treatment approaches, unmet needs, and expert
opinions on the likely disruption introduced by pipeline
agents.
About Spherix Global Insights
Spherix is a leading independent market intelligence and
advisory firm that delivers commercial value to the global life
sciences industry, across the brand lifecycle.
The seasoned team of Spherix experts provides an unbiased and
holistic view of the landscape within rapidly evolving specialty
markets, including dermatology, gastroenterology, rheumatology,
nephrology, neurology, ophthalmology, and hematology. Spherix
clients stay ahead of the curve with the perspective of the
extensive Spherix Physician Community.
As a trusted advisor and industry thought leader, Spherix’s
unparalleled market insights and advisory services empower clients
to make better decisions and unlock opportunities for growth.
To learn more about Spherix Global Insights,
visit spherixglobalinsights.com or connect
through LinkedIn.
For more details on Spherix’s primary market research reports
and interactive dashboard offerings, visit or register
here: https://clientportal.spherixglobalinsights.com
Spherix Global Insights Contacts
Jim Hickey, Gastroenterology Franchise Head
james.hickey@spherixglobalinsights.com
NOTICE: All company, brand or product names in this press
release are trademarks of their respective holders. The findings
and opinions expressed within are based on Spherix Global Insight’s
analysis and do not imply a relationship with or endorse.
Jim Hickey, Gastroenterology Franchise Head
Spherix Global Insights
4848794284
james.hickey@spherixglobalinsights.com